104 related articles for article (PubMed ID: 7546903)
21. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.
Xiang SH; Doka N; Choudhary RK; Sodroski J; Robinson JE
AIDS Res Hum Retroviruses; 2002 Nov; 18(16):1207-17. PubMed ID: 12487827
[TBL] [Abstract][Full Text] [Related]
22. Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies.
Hemming A; Gram GJ; Bolmstedt A; Losman B; Hansen JE; Ricksten A; Olofsson S
Arch Virol; 1996; 141(11):2139-51. PubMed ID: 8973529
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.
Thali M; Olshevsky U; Furman C; Gabuzda D; Posner M; Sodroski J
J Virol; 1991 Nov; 65(11):6188-93. PubMed ID: 1717717
[TBL] [Abstract][Full Text] [Related]
24. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.
McKeating JA; Bennett J; Zolla-Pazner S; Schutten M; Ashelford S; Brown AL; Balfe P
J Virol; 1993 Sep; 67(9):5216-25. PubMed ID: 7688820
[TBL] [Abstract][Full Text] [Related]
25. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
Kang CY; Hariharan K; Posner MR; Nara P
J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944
[TBL] [Abstract][Full Text] [Related]
26. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
27. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.
Moore JP; Thali M; Jameson BA; Vignaux F; Lewis GK; Poon SW; Charles M; Fung MS; Sun B; Durda PJ
J Virol; 1993 Aug; 67(8):4785-96. PubMed ID: 7687303
[TBL] [Abstract][Full Text] [Related]
28. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
29. Lymphocytotropic strains of HIV type 1 when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4.
Trischmann H; Davis D; Lachmann PJ
AIDS Res Hum Retroviruses; 1995 Mar; 11(3):343-52. PubMed ID: 7540399
[TBL] [Abstract][Full Text] [Related]
30. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
31. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.
Kang SM; Quan FS; Huang C; Guo L; Ye L; Yang C; Compans RW
Virology; 2005 Jan; 331(1):20-32. PubMed ID: 15582650
[TBL] [Abstract][Full Text] [Related]
32. An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.
Ren X; Sodroski J; Yang X
J Virol; 2005 May; 79(9):5616-24. PubMed ID: 15827176
[TBL] [Abstract][Full Text] [Related]
33. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins.
Sugiura W; Broder CC; Moss B; Earl PL
Virology; 1999 Feb; 254(2):257-67. PubMed ID: 9986792
[TBL] [Abstract][Full Text] [Related]
34. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.
Stamatatos L; Cheng-Mayer C
J Virol; 1995 Oct; 69(10):6191-8. PubMed ID: 7545244
[TBL] [Abstract][Full Text] [Related]
35. A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120.
Berkower I; Murphy D; Smith CC; Smith GE
J Virol; 1991 Nov; 65(11):5983-90. PubMed ID: 1717712
[TBL] [Abstract][Full Text] [Related]
36. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
Pantophlet R; Wilson IA; Burton DR
Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540
[TBL] [Abstract][Full Text] [Related]
37. Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity.
Choi WS; Collignon C; Thiriart C; Burns DP; Stott EJ; Kent KA; Desrosiers RC
J Virol; 1994 Sep; 68(9):5395-402. PubMed ID: 7520089
[TBL] [Abstract][Full Text] [Related]
38. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
39. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.
Garrity RR; Rimmelzwaan G; Minassian A; Tsai WP; Lin G; de Jong JJ; Goudsmit J; Nara PL
J Immunol; 1997 Jul; 159(1):279-89. PubMed ID: 9200464
[TBL] [Abstract][Full Text] [Related]
40. [Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].
Granados-González V; Piedrahita LD; Martínez M; Genin C; Riffard S; Urcuqui-Inchima S
Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):523-30. PubMed ID: 19409660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
